Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

• Main Authors: Andreas Pinter (Author), Kilian Eyerich (Author), Antonio Costanzo (Author), Alyssa Garrelts (Author), Christopher Schuster (Author), Can Mert (Author), Anastasia Lampropoulou (Author), Konstantinos Fotiou (Author), Julia-Tatjana Maul (Author), Kim A. Papp (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

AbstractPurpose Currently, in the treatment of moderate-to-severe psoriasis (PsO) there is a lack of evidence demonstrating optimal biologic treatment response with respect to disease duration. The aim of this post-hoc analysis, using real world data from the Psoriasis Study of Health Outcomes (PSoH...